---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-006238"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T12:43:11.561217+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Q1 revenue $287.6M; proprietary products up 25% YoY; GAAP EPS -$0.25, non-GAAP EPS $0.01

## Summary
- Proprietary product net sales $214.7M (+25% YoY); LYBALVI grew 173% to $38.0M.
- GAAP net loss $41.8M ($0.25 loss/share) vs $35.9M loss prior year.
- Non-GAAP net income $2.4M ($0.01 EPS) vs $19.6M ($0.12) prior year.
- Oncology separation on track for H2 2023; new company to be Mural Oncology.
- Favorable second interim award in Janssen arbitration; ~$194M back royalties due.

## SEC filing metadata
- accession: 0001564590-23-006238
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000156459023006238/0001564590-23-006238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000156459023006238/alks-8k_20230426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-006238
- JSON: https://secwatch.observer/filing/0001564590-23-006238.json
- Plain text: https://secwatch.observer/filing/0001564590-23-006238.txt

## Key facts
- Earnings Releases
  Alkermes plc. reported three months ended March 31, 2023 results: revenue $287.6 million, net income $41.8 million, EPS $0.25 loss per share. Guidance reaffirmed.
  - Period: three months ended March 31, 2023
  - Revenue: $287.6 million
  - Net income: $41.8 million
  - EPS: $0.25 loss per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Alkermes plc Reports First Quarter 2023 Financial Results — First Quarter Revenues of $287.6 Million Reflect Strong Performance of Proprietary Product Portfolio — — GAAP Loss per Share of $0.25 and Basic and Diluted Non-GAAP Earnings per Share of $0.01 — — Planned Separation of Oncology Business Expected to be Completed in Second Half of 2023 — — Second Favorable Interim Award Received in Janssen Arbitration — — Financial Expectations for 2023 Reiterated —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1520262/000156459023006238/0001564590-23-006238-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.